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| INTRODUC TI ON
Chronic kidney disease affects about 10% of the global population. 1 Over 2 million people worldwide currently receive dialysis treatment, or are recipients of a kidney transplant. Kidney transplantation is the preferred treatment for end-stage renal disease due to superior quality of life and survival rates. However, although short-term renal allograft survival has improved considerably in the last 20 years, antibody-mediated rejection (ABMR) remains one of the major causes of graft loss and of deterioration of graft function in the long-term.
Donor-specific anti-HLA antibodies (DSA) are well known to play an important role in this process. Nonetheless, (subclinical) ABMR occurs also in the absence of DSA, which has sparked interest in the short-and long-term clinical relevance of donor-reactive antibodies recognizing proteins other than HLA (ie, non-HLA-antibodies). 2 The clinical relevance of non-HLA antibodies on graft survival is not clear. 3, 4 Although it has been reported that non-HLA antibodies against Angiotensin II type 1 receptor (AT1R) are an independent risk factor for long-term graft loss, 5 others could not replicate these findings, 6, 7 which may be caused by the inclusion or exclusion of patients with pretransplant DSA. However, antibody-mediated rejection of renal allografts from HLA-identical sibling donors and also from deceased donors in the absence of pretransplant DSA has been reported several times. 8, 9 And recently it was reported that the development of circulating natural antibodies posttransplant is associated with poorer graft survival, worse graft function, and more microvascular injury. 10 Non-HLA antibodies have been described against a variety of targets, but large-scale studies incorporating analysis of these antibodies simultaneously to assess their clinical relevance in kidney transplantation are lacking. In this retrospective study on a large national cohort of 4770 renal transplant recipients, we assessed the impact on graft survival of IgG autoantibodies against 14 previously identified target proteins. 11 
| MATERIAL S AND ME THODS

| Study population
| Assessment of non-HLA antibodies
We selected 14 non-HLA target proteins from the literature. 11 Antibodies against the glomerular basement membrane protein agrin have been described in the context of transplant glomerulopathy. 12 Antibodies against adipocyte plasma membrane-associated protein (APMAP), Rho GDP-dissociation inhibitor 2 (ARHGDIB), Rho guanine nucleotide exchange factor 6 (ARHGEF6), Lamin B1, BPI fold-containing family B member 1 (LPLUNC1), protein kinase C zeta type (PRKCZ), and tubulin beta-4B (Tubb4B) were all demonstrated either in chronic hemodialysis patients or patients awaiting kidney transplantation. Antibodies directed against targets expressed on the endothelium, that is, AT1R and endothelin type A receptor (ETAR), were reported to be involved directly or indirectly in renal disease. Antibodies against the intracellular proteins vimentin and peroxisomal trans-2-enoyl-CoA reductase (PECR) have been reported to be associated with allograft failure. 13, 14 Pre-and posttransplant endorepellin antibody levels were increased in patients with vascular rejection 15 and phospholipase A2 receptor (PLA2R) antibodies are strongly associated with primary membranous nephropathy. 16 We commercially purchased all proteins with the exception of PLA2R, which was produced in-house, and coupled these proteins directly with carboxylated MagPlex Microspheres (Luminex Corp, Austin, TX) as recommended by Luminex. 17 In addition, we produced 12 of the 14 proteins with a HaloTag, with the exception of AT1R and PECR. The HaloTag proteins were coupled via a HaloTag Amine 
| Histology
Three-micrometer formalin-fixed paraffin-embedded sections were used. After antigen retrieval in citrate solution pH 6, primary antibody against ARHGDIB (Biobyt, San Francisco, CA) was applied in a 1:2000 solution for 1 hour at room temperature, followed by HRPlabeled polymer anti-rabbit Ig detection antibody (BrightVision, VWR, Duiven). Bound antibody was visualized with Nova Red substrate (Vector labs), and finally nuclei were counterstained with hematoxylin.
| Statistical analysis
Because the Kaplan-Meier estimates were biased due to unbalanced distribution of confounders, death-censored graft survival was assessed using the adjusted Kaplan-Meier estimator (AKME) based on inverse probability weighting (IPW). Each observation is weighted by its inverse probability of being in a certain group. 18 Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were derived using multivariable Cox regression. A Bonferroni correction was used to adjust for multiple comparisons when studying the effects of non-HLA antibodies on graft survival and P < .002 (.05 divided by 25 non-HLA antibodies) was considered as statistically significant (applied for analyses in Tables 1, S3, and S4). We adjusted in both the AKME and Cox regression for recipient age (quadratic) and donor age (quadratic), cold ischemia time (for donation after brain death or cardiac death), years on dialysis (quadratic), induction therapy TA B L E 1 Multivariable analyses of the effect of antibodies against ARHGDIB on 10-year death-censored graft failure
No. (%) of transplantations with anti-ARHGDIB antibodies
Hazard ratio 95% CI P-value Note: In this multivariable analysis we evaluated the effect of the presence of pretransplant ARHGDIB on the 10-year death-censored graft failure and adjusted for differences in the following covariates: recipient age (quadratic), donor age (quadratic), donor type (living or deceased, only for the total cohort), cold ischemia time in hours for donation after brain death (DBD) and donation after cardiac death (DCD), time on dialysis in years (quadratic), induction therapy with Interleukin-2 receptor-blocking antibody and the presence of pretransplant donor-specific anti-HLA antibodies against HLA-A/B/DR/DQ. CI, confidence interval. A Bonferroni correction was used to adjust for multiple comparisons with P < .002 considered as statistically significant.
with IL-2 receptor blocker, and the presence of pretransplant single 
| RE SULTS
| Determination of a clinically relevant cut-off for the presence of non-HLA antibodies
We analyzed the 4770 pretransplant sera using our multiplex non-HLA assay, and the individual median fluorescence intensitiy (MFI) values with box and whisker plots are shown in Figure S1 . As we observed relatively high background signals for some sera ( Figure S1A ), we decided to use signal-to-background ratios (STBRs) as a parameter to determine non-HLA antibody positivity. The correlation between the MFI of transferrin (directly-or HaloTag-coupled) and the MFIs of target microspheres was stronger than the correlation between MFI of other negative control microspheres and that of target microspheres (data not shown). Therefore, transferrin was selected as the most optimal negative control, and was used correspondingly to calculate the STBRs ( Figure S2 ). To determine the clinically relevant cut-off, we analyzed the impact on 1-, 5-, and 10-year death-censored graft survival of various cut-offs for each antibody in a univariate analysis ( Figure 1 ).
For each non-HLA antibody, we selected the ratio and absolute MFI cut-off that resulted in the highest difference in graft survival between the antibody-negative and antibody-positive group. For ARHGDIB, a ratio of 10 in combination with an absolute MFI of 500 was chosen as cut-off values using the directly coupled microspheres, resulting in 134/4770 (2.8%) positive patients ( Figure 1 ). An overview of the selected cut-offs for the other non-HLA antibodies based on the maximal graft survival difference is summarized in Table S1 . Depending on the type of non-HLA antibody analyzed, percentages of positive sera ranged from 0.9% to 2.8%, and varying differences were observed in 1-, 5-, and 10-year graft survival.
| Impact of pretransplant non-HLA antibodies on long-term graft survival
After Bonferroni correction, a significant difference in graft survival was observed between patients with pretransplant antibodies against ARHGDIB compared to patients without antibodies against this target (Table 1) . No significant relation with graft loss was observed for the other non-HLA antibodies. A summary of the impact of the other non-HLA antibodies on 10-year graft survival of the total cohort is summarized in Table S2 .
Because our cohort contained a relatively high proportion of living donors and we previously found that DSA had mainly an impact on deceased-donor transplantations with only a limited effect on living-donor transplantations, 19 we also analyzed the impact of non-HLA antibodies on long-term graft survival according to donor status (3276 deceased-donor and 1494 living-donor transplantations). After deceased-donor transplantation, the AKME according to the presence of ARHGDIB antibodies showed a 10-year death-censored graft survival of 61% (95% CI 50%-70%) for the 94 of 3276 patients with and 73% (95% CI 71%-75%) for the 3182/3276 patients without ARHGDIB antibodies ( Table 2 ). The multivariable analysis, adjusted for the same covariates, showed that the presence of ARHGDIB antibodies was associated with a higher risk of 10-year graft failure after transplantation with a deceased-donor kidney ( (Table S3 ). Furthermore, the rejection-free survival was comparable for patients with and without antibodies against ARHGDIB ( Figure S3 ). For the living-donor transplantations, the presence of ARHGDIB antibodies was not associated with decreased graft survival ( Figure 2B ) or increased risk of graft failure in multivariable analysis ( Table 1 , HR 1.25, 95% CI 0.59-2.66, P = .56). Finally, we also assessed the association between type of donor, anti-ARHGDIB antibodies, and 10-year graft survival in the same model. The hazard ratio for a living donor was 0.563 (95% CI 0.488-0.650, P < .0001) compared to deceased donors, suggesting that that anti-ARHGDIB was significantly associated with graft loss in recipients transplanted with a kidney from a deceased donor but not in recipients of a living-donor kidney.
| ARHGDIB expression in the kidney
Finally, we were wondering where in the kidney ARHGDIB is expressed. Therefore, we stained biopsies of a transplanted kidney without histological abnormalities and a transplanted kidney with acute tubular necrosis using an anti-ARHGDIB antibody. In a transplanted kidney without histological abnormalities, weak ARHGDIB expression was seen in endothelial cells of interlobular arteries, endothelial cells of peritubular capillaries, and endothelial cells of glomerular capillaries ( Figure 3A) . In a transplanted kidney with acute tubular necrosis, strong ARHGDIB expression was seen in endothelial cells of interlobular arteries, endothelial cells of peritubular capillaries, and endothelial cells of glomerular capillaries. In addition, F I G U R E 1 Impact of cut-off for the presence of non-HLA antibodies against ARHGDIB on graft survival. A, In this figure the hypothesis is displayed that the presence of a non-HLA antibody is associated with graft failure. B, Using acquired data from non-HLA measurements, we determined the difference in graft survival between the non-HLA antibody negative and positive group for various cut-off values at 1, 5, and 10 years after transplantation in a univariate Kaplan-Meier analysis. Here, the results for directly coupled ARHGDIB are used as an example. The highest difference in graft survival between the ARHGDIB-positive and -negative group was achieved with a cut-off for signal-tobackground ratio of 10 in combination with a cut-off for absolute MFI of 500. The graft survival difference for this cut-off between the ARHGDIB-positive and -negative group was 5.9%, 10.9%, and 13.1% at 1, 5, and 10 years after positive staining for ARHGDIB is also seen in some podocytes and lymphocytes ( Figure 3B ).
| D ISCUSS I ON
In the present study, we determined the relation between graft fail- Antibodies against AT1R were associated with rejection and graft survival according to results from several large-scale studies, 5, 20 although a recent large study (n = 940) did not confirm this association. 4 Pretransplant anti-ETAR antibodies have been associated with higher serum creatinine values at 1 year posttransplantation and with more severe vascular rejection. 21 Antibodies against
LG3, a C-terminal fragment of perlecan, were associated with acute tubulointerstitial rejection and long-term renal allograft dysfunction. 15, 22 Antibodies against PLA2R, LPLUNC, APMAP, and PRKCZ were described previously in small case-series and have not been further evaluated. [23] [24] [25] During the development of our non-HLA antibody assay we found that MFI results on a specific bead was comparable between singleplex and multiplex measurement, indicating no occurrence of compromise by multiplex analysis. In general, non-HLA antibodies frequently occur within the healthy population and for many autoantibodies a serum is considered positive when exceeding a cut-off yielding a limited (<5%) frequency of positive results within the healthy population. This definition does not necessarily provide the most clinically relevant cut-off value with regard to prognosis. To this end, we chose to define a clinically relevant cut-off as it was previously described for HLA antibodies using a combination of STBR combined with a minimal MFI level. 26 Using individual cut-offs for each non-HLA antibody, optimally discriminating patients with long-term functioning grafts vs graft loss, we did not find associations between the presence of any of the abovementioned previously studied non-HLA antibodies and graft loss, function, or rejection. We did not analyze the autoantibody MFI levels as continuous variables, because in the field of anti-HLA antibodies it is well accepted that MFI is not an indication of antibody titer and is influenced by sev- In our study, non-HLA proteins were coated directly or indirectly (via HaloTag) to the microspheres. This strategy was chosen because the coupling process may influence the conformation and accessibility of epitopes predominantly recognized on non-HLA beads. 11 Previously we found that the correlation between results obtained with our test and with commercial assays depended on the coupling method of the proteins. This demonstrates the necessity of complete transparency and detailed description of methods when comparing the effects of non-HLA antibodies in patient groups. Because there are no commercially available reference sera against the non-HLA antibodies we selected, we were not able to properly compare our Luminex assay to other commercially available ELISA or Luminex autoantibody assays. In the sera used in our multiplex assay, we measured non-HLA IgG antibodies. It is possible that some non-HLA antibodies relevant to prognosis are of another isotype and were not detected here. In some autoimmune diseases, autoantibodies are of other isotypes, such as IgM-RF or IgA-anti-tTG. However, most clinically relevant autoantibodies are of the IgG isotype. We also examined whether a reactivity pattern between non-HLA antibodies can be distinguished, for instance due to cross-reactivity, but we did not find significant associations between each of the 14 non-HLA antibodies investigated and there was no relationship with pretransplant DSA.
In a large cohort studied by Opelz, a 9% difference in 10-year graft survival was observed between recipients of HLA-identical sibling donors with or without panel-reactive HLA antibodies, which led to the conclusion that a high immunization grade against HLA may indicate an increased immunity against non-HLA. 33 In our study, the observed adverse effects of non-HLA antibodies were independent of the presence of DSA as we adjusted for this covariable. Because ARHGDIB is considered to be a minor histocompatibility antigen, we examined the relation between antibody levels and potentially immunizing events, but found no link with repeat transplantation, female sex, pregnancies, or potentially confounding factors such as diabetes type 1, or several primary renal diseases. Therefore, mechanisms may be involved in the induction of non-HLA antibody formation other than the well-known sensitizing events stimulating HLA antibody production.
We were not able to include posttransplant samples (sera and/or biopsies) in our study, thereby limiting the use of results in pretransplant risk stratification. Future studies have to be performed to evaluate whether posttransplant monitoring of anti-ARHGDIB is useful. Another limitation of the study was that we did not have detailed clinical information, such as autoimmune diseases or hypertension, to potentially link the presence of anti-ARHGDIB antibodies to a clinical parameter.
Due to lack of detailed rejection and histology information, we cannot directly link anti-ARHGDIB antibodies with the rejection phenotype.
In conclusion, our study demonstrates that pretransplant non-HLA antibodies against ARHGDIB are a significant risk factor in deceased-donor transplantation. These antibodies occur independently from DSA or other non-HLA antibodies investigated. It is currently unknown whether the presence of these antibodies is a biomarker, as is the case in many autoimmune diseases, or whether they play a role in the pathogenesis of graft loss. Although validation of our findings in independent cohorts is necessary, based on these results, we suggest that pretransplant risk assessment can be improved by measuring these antibodies in all patients awaiting deceased-donor transplantation.
ACK N OWLED G M ENTS
The 
